Press Releases

View: All Categories General Releases Financial Releases Year: All Years 2008 2007 2006 2005 2004 All Releases Oncothyreon Reports First Quarter 2008 Financial Results May 7, 2008 15.0 KB   BELLEVUE, WA, May 7, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported a net loss of $5.1 million or $0.26 per basic and diluted share for the quarter ended March 31, 2008, compared with $4.7 million or $0.24 per basic and diluted share for the comparable period in 2007. All ... Read more Oncothyreon files investigational new drug application for PX-866 oncology compound May 1, 2008 12.4 KB   BELLEVUE, WA, May 1, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for PX-866, a small molecule phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor for the treatment of advanced c... Read more Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting Apr 16, 2008 15.2 KB   BELLEVUE, WA, Apr 16, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from pharmacokinetic studies of PX-12 and preclinical studies of PX-866 were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, held April 12-16, 2008. Informat... Read more Oncothyreon's PX-478 enhances antitumor effects of radiation therapy in preclinical models of pancreatic and brain cancer Apr 15, 2008 13.2 KB   BELLEVUE, WA, Apr 15, 2008 (Canada NewsWire via COMTEX News Network) -- Results Presented at AACR Annual Meeting Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, an investigational small molecule cancer therapy, were presented yesterday by David L. Schwartz, M.D, University of Texas M.D. An... Read more Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting Apr 10, 2008 12.7 KB   BELLEVUE, WA, Apr 10, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced today that data from preclinical studies of PX-478, pharmacodynamic studies of PX-12 and preclinical studies of PX-866 will be presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego... Read more Oncothyreon announces effectiveness of shelf registration statement Apr 9, 2008 8.9 KB   BELLEVUE, WA, April 9, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that the Securities and Exchange Commission has declared effective Oncothyreon's registration statement on Form S-3 (File # 333-149837). The registration statement allows Oncothyreon to offer and sell from time to... Read more Oncothyreon announces issuance of patent for PX-867 Mar 20, 2008 12.0 KB   BELLEVUE, WA, Mar 20, 2008 (Canada NewsWire via COMTEX News Network) -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) today announced that the U.S. Patent and Trademark office has issued a patent for PX-867, a small molecule compound currently in preclinical development. The newly issued patent, U.S. Patent No. 7,335,679, includes claims covering both... Read more Oncothyreon to present at upcoming investment conferences Mar 12, 2008 9.0 KB   BELLEVUE, WA, March 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at... Read more Oncothyreon reports full year and fourth quarter 2007 financial results Mar 10, 2008 17.3 KB   BELLEVUE, WA, March 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today reported financial results for the year and quarter ended December 31, 2007. All results are in U.S. dollars and prepared using U.S. GAAP. Net loss for the year ended December 31, 2007, was $20.3 millio... Read more Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call Mar 7, 2008 9.1 KB   BELLEVUE, WA, March 7, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (the "Company") (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it intends to release its fourth quarter and full year 2007 financial re... Read more Oncothyreon's PX-478 is effective in preclinical model of human lung cancer Feb 25, 2008 12.6 KB   BELLEVUE, WA, Feb 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq - ONTY) (TSX - ONY) (the "Company") today announced the presentation of data demonstrating the effectiveness of PX-478 in a preclinical model of human lung cancer at the 8th Annual Targeted Therapies of the Treatment of Lung Cancer meeting of the I... Read more Oncothyreon launches new corporate website Feb 5, 2008 9.4 KB   BELLEVUE, WA, Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced the launch of its new corporate website at www.oncothyreon.com. "We are excited about our... Read more Oncothyreon to present at BIO CEO & Investor Conference Feb 4, 2008 8.9 KB   BELLEVUE, WA, Feb 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at t... Read more Oncothyreon highlights corporate and clinical objectives for 2008 Jan 28, 2008 15.0 KB   BELLEVUE, WA, Jan 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Oncothyreon Inc. (the "Company") (Nasdaq: ONTY) (TSX:ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today provided a review of the Company's clinical development plans and corporate objectives f... Read more Oncothyreon Regains Compliance with NASDAQ Minimum Bid Listing Requirement Jan 2, 2008 8.9 KB   Bellevue, Washington — January 2, 2008 — Oncothyreon Inc. (NASDAQ: ONTY, TSX:ONY) today announced that it has received a letter from The Nasdaq Stock Market, indicating that the Company has regained compliance with the $1.00 per share minimum closing bid price requirement for continued listing on the Nasdaq Global Market, pursuant... Read more Oncothyreon to Receive $5 Million Payment Dec 17, 2007 12.9 KB   Bellevue, Washington — December 17, 2007 — Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced that it has completed the transfer of certain assays and methodology related to Stimuvax® (BLP25 liposome vaccine) to Merck KGaA of Darmstadt, Germany, triggering a payment to Oncothyreon of $5 million. The payment will be made un... Read more Oncothyreon to Begin Trading Today on Nasdaq and TSX Dec 11, 2007 10.6 KB   Bellevue, Washington — December 11, 2007 — Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) today announced that its common stock will begin trading on the Nasdaq Global Market under the symbol ONTY and on the Toronto Stock Exchange under the symbol ONY at the opening of trading today. Oncothyreon Inc. is the new name for the former Biom... Read more Court Issues Final Order Approving Biomira's Move to U.S. and Name Change to Oncothyreon Dec 5, 2007 5.3 KB   EDMONTON, ALBERTA, CANADA - December 5, 2007 - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) ("Biomira", the "Company") announced that the Alberta Court of Queen's Bench today issued a Final Order approving the plan of arrangement under which the Company will move to the United States and change its name to Oncothyreon Inc. ("Oncothyreon"). Bio... Read more Biomira Shareholders Approve Move to U.S. Dec 4, 2007 5.7 KB   EDMONTON, ALBERTA, CANADA - December 4, 2007 - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) ("Biomira", the "Company") today announced that the Company's shareholders have approved a plan of arrangement under which the Company will move to the United States and change its name to Oncothyreon Inc. ("Oncothyreon"). The approval came at a special... Read more Biomira inc. Announces date for Special Meeting of Shareholders; Oncothyreon inc. Registration Statement Declared Effective Nov 1, 2007 7.9 KB   EDMONTON, ALBERTA and BELLEVUE, WASHINGTON - November 1, 2007 - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) (the "Company") today announced that it will hold a special meeting of shareholders at 9:00 a.m. Mountain Time on December 4, 2007, at the Delta Edmonton South Hotel & Conference Centre, 4404 Gateway Blvd., Edmonton. The meeting wil... Read more Showing 1-20 of 117 Page: 1 2 3 ... 6  Next 20 = add release to Briefcase return to top ^